Shell Asset Management Co. bought a new position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,207 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.
Several other large investors also recently modified their holdings of SHPG. Duncker Streett & Co. Inc. bought a new stake in shares of Shire PLC during the second quarter worth about $111,000. West Oak Capital LLC bought a new stake in shares of Shire PLC during the second quarter worth about $126,000. NEXT Financial Group Inc bought a new stake in shares of Shire PLC during the second quarter worth about $126,000. North Star Investment Management Corp. bought a new stake in shares of Shire PLC during the second quarter worth about $147,000. Finally, OLD Second National Bank of Aurora bought a new stake in shares of Shire PLC during the second quarter worth about $161,000. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded up 1.71% on Thursday, hitting $191.05. The stock had a trading volume of 827,397 shares. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The company has a 50-day moving average price of $194.88 and a 200-day moving average price of $187.59. The stock has a market capitalization of $56.91 billion, a price-to-earnings ratio of 39.70 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. During the same quarter last year, the firm posted $2.63 EPS. The firm’s revenue for the quarter was up 55.9% on a year-over-year basis. Equities analysts predict that Shire PLC will post $12.92 earnings per share for the current year.
The company also recently disclosed a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were issued a $0.139 dividend. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 15.63%.
A number of equities research analysts recently weighed in on the stock. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a research report on Tuesday, June 28th. HSBC downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Shire PLC in a research report on Monday, October 3rd. Piper Jaffray Cos. set a $201.00 price objective on shares of Shire PLC and gave the company a “hold” rating in a research report on Saturday, October 1st. Finally, Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a research report on Saturday, August 13th. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $232.75.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.